Peptide library / Immune & defense / Enfuvirtide
Enfuvirtide
A 36 amino acid injectable HIV drug, the first fusion inhibitor.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- HIV-1 infection with resistance to other drugsFDA approved
How it is thought to work
Enfuvirtide mimics part of the HIV envelope and blocks the virus from fusing with the host cell.
What the evidence shows
TORO trials showed a lower viral load when added to an optimized regimen in treatment-experienced patients.
Safety and unknowns
Injection site reactions are almost universal, and bacterial pneumonia was seen more often than expected.
Regulatory status
FDA-approved as Fuzeon in 2003. It is now rarely used because of newer drugs.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Immune & defense
Glatiramer acetate
FDA-approvedA random mixture of four amino acids used in relapsing multiple sclerosis.
Icotrokinra
In clinical trialsAn oral peptide that blocks the IL-23 receptor, developed for psoriasis.
Echinocandins
FDA-approvedA class of cyclic lipopeptide antifungals and first-line treatment for invasive Candida infections.
General information, not medical advice. Do not buy or inject unregulated peptides.